

Manager of Company Announcements
ASX Limited
Level 6
20 Bridge Street
SYDNEY NSW 2000

4 December 2009
By e-lodgement

**AUSTRALIAN FEDERAL COURT APPROVES THE CONVENING OF SCHEME MEETINGS
TO VOTE ON PROPOSED REDOMICILIATION IN THE UNITED STATES OF AMERICA**

The Directors of Unilife Medical Solutions Limited (**Company**) today announced that they have received approval from the Australian Federal Court to convene meetings of the Company's shareholders and optionholders (collectively **Security Holders**) to vote on the proposed redomiciliation of the Unilife Group in United States of America (**Proposed Transaction**) as announced to ASX on 1 September 2009. This is an important step in the Redomiciliation process.

Scheme Meetings

The Proposed Transaction will be implemented by way of two separate schemes of arrangement between the Company and its shareholders (**Share Scheme**) and the Company and its optionholders (**Option Scheme**) respectively.

The scheme meetings will be held on **Friday, 8 January 2010** at the Westin Hotel, 1 Martin Place, Sydney NSW 2000 at the following times:

- the Share Scheme meeting will commence at 10.00am; and
- the Option Scheme meeting will commence at 10.30am or immediately following the conclusion of the Share Scheme meeting (if later).

Security Holders of the Company as at 7.00pm on 6 January 2010 will be eligible to vote at the Scheme Meetings.

As previously announced, an Extraordinary General Meeting (**EGM**) to approve a new employee incentive scheme for Unilife Corporation, the issue of options to certain Directors of the Company and a new incentive package for the Company's Chief Executive Officer, Alan Shortall, will also be held on 8 January 2010 at 11.00am or immediately following the conclusion of the Scheme Meetings (if later).

**Unilife Medical
Solutions Limited**

For personal use only

Information Memorandum

An Information Memorandum containing details of the Share Scheme and Option Scheme and other important information for Security Holders, including details of how to vote on the Schemes, an Independent Expert's Report with respect to the fairness of the schemes to Security Holders, and an explanation of the tax implications of the Proposed Transaction will be mailed to Security Holders on 9 December 2009. The Information Memorandum will be accompanied by a Notice of Extraordinary General Meeting including an explanatory statement in relation to the resolutions to be proposed at the EGM.

Independent Expert's opinion

The Board of Directors has appointed PKF Corporate Advisory (East Coast) Pty Limited (**PKF**) as an independent expert to assess whether the schemes are in the best interests of Security Holders. PKF has formed the view that the Proposed Transaction is:

"fair and reasonable to, and hence in the best interest of, the shareholders as a whole and also in respect of the optionholders as a whole."

Recommendation

The Board of Directors consider that the Share Scheme and the Option Scheme are in the best interests of Security Holders and unanimously recommend that Security Holders vote in favour of the resolutions to be proposed at the Scheme Meetings.

Security Holder Enquiry Line

To assist all Security Holders, the Company will establish telephone enquiry lines to address questions that Security Holders may have in relation to the Proposed Transaction, as follows:

Australia (toll free)	Phone: +1800 632 680
US (toll free)	Phone: +1 866 496 5819
International	Phone: +61 2 8256 3394

The enquiry lines will be opened when the Information Memorandum has been mailed.

Security Holders should also should consult their legal, financial or other professional adviser as appropriate.

—ends—

Shareholder / Analyst Enquiries:

Australia	Jeff Carter	Phone: + 61 2 8346 6500
United States	Stuart Fine	Phone: + 1 908 469 1788

About Unilife

Unilife Medical Solutions Ltd is an ISO 13485 certified company that designs, develops and supplies innovative safety medical devices. Listed on the Australian Securities Exchange (ASX : UNI) since 2002, Unilife has FDA-registered manufacturing facilities in the US State of Pennsylvania and a proprietary portfolio of clinical and prefilled safety syringes designed for use within healthcare and pharmaceutical markets.

For personal use only